研究疾病:
|
慢性肾脏病
|
研究疾病代码:
|
|
Target disease:
|
Chronic Kidney Disease
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
探索性研究/预试验
Pilot clinical trial
|
研究目的:
|
1.观察消瘀泄浊饮对CKD3-4期气虚夹瘀型及其并发症(如MIAS等)的疗效。
2.探究消瘀泄浊饮对机体Th17/Treg免疫平衡的影响及在CKD微炎症状态发生发展中的作用。
3.证明消瘀泄浊饮影响ACE2-Ang(1-7)-MAS/ACE-AngII-AT1R轴平衡来延缓CKD的进展。
|
Objectives of Study:
|
1. To observe the effects of Xiaoyu Xiezhuo Decoction on Chronic kidney disease in stage 3-4 with deficiency of vital energy and stagnation of blood and its complications (like MIAS, etc.).
2. To explore the effect of Xiaoyu Xiezhuo Decoction on Th17 / Treg immune balance and its role in the occurrence and development of CKD micro inflammation.
3. To prove that Xiaoyu Xiezhuo decoction can delay the progress of CKD by affecting the balance of ACE2-Ang(1-7)-MAS/ACE-AngII-AT1R axis.
|
药物成份或治疗方案详述:
|
|
Description for medicine or protocol of treatment in detail:
|
|
纳入标准:
|
1.符合西医CKD3-4期诊断标准的患者;
2.符合中医气虚夹瘀证标准;
3.年龄为18~75岁,性别不限,且尚未接受透析治疗者;
4.经基础降压,血压≤140/90mmHg者;
5.近3个月血肌酐(Scr)变化在15%之内,血红蛋白(Hb)>100g/L,无严重酸中毒发生;
6.24h尿蛋白定量(24hUpr)≤2.5g(至少连续测定2次,取均值);
7.原发病为慢性肾小球肾炎、高血压、糖尿病、乙肝相关性肾炎等,且病情控制稳定;
8.患者同意本研究治疗,加入慢病管理,并签署知情同意书;
9.近3个月内未进行其他药物测试或已经过有效的药物洗脱期。
|
Inclusion criteria
|
1. Patients who meet the Western medicine CKD 3-4 diagnostic criteria;
2. Meet the standard of Qi deficiency and blood stasis syndrome in TCM;
3. Those who are 18 to 75 years old, have no gender limit, and have not yet received dialysis treatment;
4. After basic blood pressure reduction, blood pressure <= 140/90mmHg;
5. The blood creatinine (Scr) change within 15% in the past 3 months, hemoglobin (Hb)> 100g/L, no serious acidosis occurred;
6.24h urine protein quantification (24hUpr) <= 2.5g (at least two consecutive determinations, take the average);
7. The primary disease is chronic glomerulonephritis, hypertension, diabetes, hepatitis B-related nephritis, etc., and the condition is stable;
8. The patient agrees to the treatment of this study, joins the chronic disease management, and signs an informed consent form;
9. No other drug test has been performed in the past 3 months or the effective drug wash-out period has passed.
|
排除标准:
|
1.正在接受激素、非甾体抗炎药或免疫抑制剂治疗;
2.严重心律失常、急性心衰、心肌梗死、急性脑卒中、不稳定心绞痛、NYHA分级IV级(纽约心脏病协会心功能分级标准);
3.合并急性感染性疾病,存在手术、创伤应激的患者;合并慢性传染病如慢性乙型肝炎活动期及迁延期、肝硬化失代偿期或活动性结核等患者;
4.伴有严重脏器功能损害影响患者生存的疾病,如恶性肿瘤、HIV感染等;
5.合并心血管、血液系统、神经系统、消化系统、呼吸系统等严重原发性疾病者,有明显出血倾向者;
6.并发高钾血症、心力衰竭等危及生命者;
7.入组前3个月内GFR波动范围≥30%;
8.严重过敏体质,对该研究中已知某些药物过敏或无法耐受者;
9.孕期或哺乳期患者;
10.近3个月有大出血或输血史,有严重临床感染、酸中毒迹象者;
11.有精神病病史或者沟通认知功能障碍等依从性差无法合作的患者;
12.非黄种人。
|
Exclusion criteria:
|
1. Being treated with hormones, non-steroidal anti-inflammatory drugs or immunosuppressive agents;
2. Severe arrhythmia, acute heart failure, myocardial infarction, acute stroke, unstable angina, NYHA classification IV (New York Heart Association Heart Function Classification Standard);
3. Patients with acute infectious diseases, surgery and traumatic stress; patients with chronic infectious diseases such as chronic hepatitis B active and prolonged, decompensated liver cirrhosis, or active tuberculosis;
4. Diseases that are accompanied by severe organ damage that affect the survival of patients, such as malignant tumors, HIV infection, etc.;
5. Patients with severe primary diseases such as cardiovascular, blood system, nervous system, digestive system, respiratory system, etc., and those with obvious bleeding tendency;
6. Complicated with hyperkalemia, heart failure and other life-threatening persons;
7. GFR fluctuation range >= 30% within 3 months before enrollment;
8. Severe allergies, allergic or intolerant to certain drugs known in the study;
9. Patients during pregnancy or lactation;
10. Those who have had a history of hemorrhage or blood transfusion in the past 3 months, and have signs of serious clinical infection or acidosis;
11. Patients who have a history of mental illness or communication and cognitive dysfunction and other poor compliance who cannot cooperate;
12. Non-yellow race.
|
研究实施时间:
Study execute time:
|
从From
2021-01-01
至To
2024-12-31
|
征募观察对象时间:
Recruiting time:
|
从From
2021-07-01
至To
2023-02-28
|